Biomedical Occupation or Discipline – Page 2

Eli Lilly Picks Houston for $6.5 Billion API Manufacturing Facility

3 weeks ago talkbio0Tagged alpha 1-antitrypsin, cardiometabolic, Eli, Eli Lilly, Generation Park, Houston, Immunology, Investments, Manufacturing, Neoplasms, Neuroscience discipline, pharmaceutical manufacturing, small molecule medicines

Eli Lilly; Houston; API manufacturing; $6.5 billion investment; Generation Park; small molecule medicines; pharmaceutical manufacturing; cardiometabolic; oncology; immunology; neuroscience

Fierce Biotech Fundraising Tracker ’25: Avenzo adds $60M Series B; Ollin debuts with $100M

3 weeks ago talkbio0Tagged Antibodies, Bispecific, Avenzo, Clinical Trials, Neoplasms, Ollin Biosciences, Ophthalmology specialty, pipeline development, Series B financing, venture capital

Avenzo Therapeutics; Series B financing; Ollin Biosciences; biotech fundraising; oncology; ophthalmology; venture capital; pipeline development; bispecific antibody; clinical trials

Pfizer Acquires Metsera to Compete with Zepbound in Obesity Market

3 weeks ago talkbio0Tagged Acquisition, Amylin, Clinical Trials, dosing, Glucagon-Like Peptide 1, MET-097i, MET-233i, Metsera, mimetics, monthly, Obesity, Pfizer, Zepbound

Pfizer; Metsera; obesity treatment; Zepbound; GLP-1 therapies; MET-233i; monthly dosing; amylin mimetic; MET-097i; acquisition; clinical trials

Langers Team Launch $77.5M Fund to Invest at Intersection of Technology and Biology

4 weeks ago talkbio0Tagged biology (field), Capital, Fund I, Geographic Intersection, Investments, Michael Langer, Robert Langer, Technology, venture capital

T.Rx Capital; Robert Langer; Michael Langer; intersection of technology and biology; biotech investments; venture capital; Fund I

Novartis Inks Second Molecular Glue Deal With Monte Rosa Worth Up to $5.7 Billion

4 weeks ago talkbio0Tagged Autoimmune Diseases, Collaboration, Drug Discovery, Immunology, molecular glue degraders, Monte Rosa Therapeutics, Novartis, QuEEN, royalties, upfront payment

Novartis; Monte Rosa Therapeutics; molecular glue degraders; $5.7 billion deal; drug discovery; immunology; QuEEN platform; autoimmune diseases; upfront payment; royalties; collaboration

Lila Sciences Raises $235M to Expand AI Science Factories

4 weeks ago talkbio0Tagged Artificial Intelligence, Autonomous Research, Biotechnology, Funding, Lila Sciences, Series

Lila Sciences; AI Science Factories; Autonomous Research; Biotechnology; Series A Funding

FDA Begins Publishing Complete Response Letters for Ongoing Drug Applications in Real Time

1 month ago talkbio0Tagged Application procedure, drug applications, openFDA, public health medicine (field), radical transparency, real-time disclosure, regulatory transparency, Response Letters, United States Food and Drug Administration

FDA; complete response letters; real-time disclosure; drug applications; radical transparency; pending applications; regulatory transparency; public health; openFDA

Trump Administration Weighs Severe Restrictions on US Pharmas Licensing Chinese Medicines

1 month ago talkbio0Tagged AstraZeneca, chinese medicine, Drug Industry, drug manufacturing, executive order, licensing restrictions, lobbying, National Security, Pfizer, Transplant Registry Unified Management Program, United States Food and Drug Administration

Trump administration; Chinese medicines; executive order; pharmaceutical industry; licensing restrictions; national security; lobbying; Pfizer; AstraZeneca; biotech; drug manufacturing; FDA review

Second MAHA Report Emphasizes Chronic Disease, Tilts at Vaccine Reform

1 month ago talkbio0Tagged childhood health, childhood vaccine schedule, Chronic disease, Commission, federal directives, Food Policy, MAHA, Prescription Drug Overuse, public health medicine (field), Robert F. Kennedy Jr., Vaccine Reform

MAHA Commission; chronic disease; vaccine reform; Robert F. Kennedy Jr.; childhood health; food policy; medication overuse; public health; federal directives; childhood vaccine schedule

Regeneron and Sandoz Settle Eylea Biosimilar Patent Dispute

1 month ago talkbio0Tagged Approved, Biosimilars, Enzeevu, Eylea, launch, Ophthalmology specialty, Patent Settlement, Regeneron, sandoz, United States, United States Food and Drug Administration

Regeneron; Sandoz; Eylea; Enzeevu; biosimilar; aflibercept; patent settlement; FDA approval; U.S. launch; ophthalmology